From the Editor - Pharmaceutical Executive


From the Editor
The industry and its issues, from editor-in-chief William Looney.

The Peace Dividend

July 10, 2014

A surprising takeaway from the recent BIO Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.

Pharma 50 Trends: Past, Present, and Future

June 9, 2014

Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand, writes William Looney.

What's Real in Deals

May 1, 2014

Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.

Mission Critical: Assessing Pharma's Drivers of Change

April 24, 2014

Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.

Dividing Lines

April 1, 2014

Three examples from Pharm Exec's coverage this month show that, in our industry, there are always two sides—at least—to every question.

The Community Ethic

March 1, 2014

Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered. A revolution in the making, where legislation combined with market forces as well as community and stakeholder advocacy are adding fresh momentum to a population-based approach to health practice. Population health focuses on a system built around three pillars of care: preventive care, primary care, and coordinated care, all driven by a single performance metric, which is value, as evidenced through quality and outcomes. Executing around this integrative model depends entirely on partnerships, especially with non-traditional players like the physician assistant.

A Spark From GSK

February 1, 2014

Today, there is promise in new approaches that rely on the "other language of biology," using the human body's own circuitry of cells and nerves to induce precisely targeted therapeutic effects against a range of debilitating diseases.

Russian Innovation: A Higher Mark

February 1, 2014

For the first time, the spotlight shines on Russia's potential in biotechnology and pharma products

For Russia—Tough Love

January 21, 2014

Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exst. Drugs were still classified as chemicals, developed from the random screening of many thoughts.


Click here